[1] Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET[J]. Eur J Nucl Med, 2002, 29(3): 361-366.
[2] EI-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium 99m-MIBI versus fluorine-18 FDG in diffuse multiple myeloma[J]. J Nucl Med, 1997, 38(8): 1208-1210.
[3] Orchard K, Barrington S, Buscombe J, et al. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma[J]. Br J Hematol, 2002, 117(1): 133-135.
[4] Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m seatamibi in patients with multiple myeloma and potential role in the follow-up[J]. Eur J Nucl Med,2001, 28(3): 304-312.
[5] Alexandrakis MG, Kyriakou DS, Passam F, et al. Value of Tc-99m seatamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate[J]. Ann hematol, 2001, 80(6): 349-353.
[6] Watanabe N, Shimizu M, Kageyama M, et al. Multiple myelomaevaluated with 201Tl scintigraphy compared with bone scintigraphy[J]. J Nucl Med, 1999, 40(7): 1138-1142.
[7] Ishibashi M, Nonoshita M, Uchida M, et al. Bone marrow uptake of thallium-201 before and after therapy in multiple myeloma[J]. J Nucl Med, 1998, 39(3): 473-475.
[8] Sohn SK, Ahn BC, Lee SW, et al. Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma[J]. Eur J Nucl Med, 2002, 29(5): 591-596.